Fulgent Genetics Reports Q3 2026 Results, Revenue Up 8%
Fulgent Genetics said third-quarter 2026 revenue grew 8% year over year and losses narrowed. It also improved its full-year 2026 non-GAAP loss guidance.
Fulgent Genetics, Inc. announced its financial results for the third quarter of 2026 on November 5, 2026. The company achieved 8% year-over-year revenue growth, supported by the ongoing integration of its Bako and StrataDx subsidiaries and improvements in collection processes. As a result of these sequential gains, the company saw its losses narrow and improved its non-GAAP loss guidance for the full fiscal year 2026.
Management noted that billing-system initiatives and collection performance relative to historical levels remain key factors influencing the company's financial trajectory.